Maximize Info from Minimal Amount of Samples!
Explore Beyond Limits: Minuscule Sample? No Problem!
Insights from Multiplex Assays: Small Samples, Big Impact!
Monitor Multiple Genes and Proteins with Minimal Sample.
Richer Gene and Protein Info from Fewer Cells!
Quantify any Proteins and those "Undetectable".
Visionary Research, Passionate Team, Revolutionizing Cancer Immunotherapy!
Save Sample, Time, & Money!

Immuno-Oncology Services

In Vitro Immune Cell Function Assays 

T Cell  Activation and Proliferation

  • T cell activation and proliferation using MLR, anti-CD3/CD28; PHA/Con A, PMA/ionomycin, SEA/SEB, anti-PD1, or anti-CTLA4) (Flow Cytometry or BrdU assay)
  • Antigen-specific recall response assay
  • Screening for the ability to reverse T cell exhaustion
  • Suppression assay with Treg cells 
  • Modulation of differentiation and cytokine profile
  • Immune cell migration/Chemotaxis assay
  • Mixed lymphocyte reaction (PBMC/T cell/DC, one way or two-way)
  • Immune checkpoint blockade assay
  • Cytokine secretion profile (ELISA, Luminex, ELISpot)
  • T Cell Surface marker expression analysis (Flow Cytometry)

Macrophages and Dendritic Cell Targets

  • Target expression profiling on subsets (resting vs activated)
  • Screening for modulation of M1/M2/MDSC (e.g. differentiation)
  • Screening for modulation of tumor conditional response (phenotype and cytokine/chemokine production)
  • Effects on antigen presentation
  • Antibody-dependent cellular phagocytosis (ADCP)

NK Cell Targets

  • Target expression on NK cells
  • Modulation of activation and killing
  • Antibody-dependent cellular cytotoxicity (ADCC)

B Cell Targets

  • Target expression profiling on B cell subsets (resting and activated)
  • Modulation of antibody production
  • Modulation of antigen presenting cell function and cytokine release
  • BCR signaling (BTK, CARD11/BCL10/MALT1 complex)

Mast Cell and Basophil Targets

  • Degranulation and histamine release
  • Cell migration and chemotaxis

In Vitro Tumor Cell Killing Assays 

Tumor Targets

  • Target expression profiling on subsets
  • Effects on antigen presentation/killing assays
  • Modulation of checkpoint ligand expression
  • Modulation of tumor derived immune modulating factors (e.g. eicosanoids, chemokines, cytokines)
  • Direct cytotoxicity (~100 cancer cell lines available for screening)

Immune Cell Mediated Cancer Cell Killing 

  • ADCC (antibody-dependent cell-mediated cytotoxicity assays)
  • CDC (complement-dependent cytotoxicity assays)
  • ADCP (antibody-dependent cellular phagocytosis)
  • T cell killing – LDH/DELFIA assay
  • NK mediated cell killing assay (FACS based)

Novel Immuno-OncologyTarget Screening

  • Biochemical and cell-based screening assays for novel immunotherapy.  IC50 determination for small or large molecules against immune targets for: 

    PD-1: PD-L1/2, PD-L1:B7-1, CTLA4:B7-1, CTLA4:B7-2, BTLA: HVEM, CD28:B7-1, CD40: CD40L, CD47: Sirpα, CD137:CD137L, OX40:OX40L, GITR: GITRL, TIGIT: CD155, IDO/TDO, COX1/COX2